Telix Pharmaceuticals (NASDAQ:TLX) Rating Lowered to Sector Perform at Royal Bank Of Canada

Telix Pharmaceuticals (NASDAQ:TLX) was downgraded by Royal Bank Of Canada from an “outperform” rating to a “sector perform” rating in a report issued on Friday, MarketBeat reports.

Several other research firms have also issued reports on TLX. Weiss Ratings reiterated a “sell (d)” rating on shares of Telix Pharmaceuticals in a report on Monday, April 20th. Citigroup decreased their price target on Telix Pharmaceuticals from $22.50 to $22.00 and set a “buy” rating for the company in a research note on Tuesday, July 7th. Wall Street Zen raised Telix Pharmaceuticals from a “sell” rating to a “hold” rating in a research report on Saturday, April 11th. HC Wainwright reiterated a “buy” rating and set a $20.00 price objective on shares of Telix Pharmaceuticals in a research note on Tuesday, July 7th. Finally, Wedbush reissued an “outperform” rating and issued a $22.00 price objective on shares of Telix Pharmaceuticals in a report on Monday, July 6th. One equities research analyst has rated the stock with a Strong Buy rating, four have given a Buy rating, two have given a Hold rating and one has given a Sell rating to the company’s stock. According to MarketBeat, Telix Pharmaceuticals presently has a consensus rating of “Moderate Buy” and an average price target of $20.40.

Telix Pharmaceuticals Price Performance

Telix Pharmaceuticals stock opened at $10.46 on Friday. The firm has a 50-day moving average of $10.36 and a 200-day moving average of $9.06. The company has a debt-to-equity ratio of 1.08, a quick ratio of 1.27 and a current ratio of 1.43. Telix Pharmaceuticals has a one year low of $6.28 and a one year high of $16.94.

Insider Transactions at Telix Pharmaceuticals

In other news, CEO Christian Behrenbruch acquired 33,435 shares of Telix Pharmaceuticals stock in a transaction dated Wednesday, April 29th. The stock was bought at an average price of $14.87 per share, for a total transaction of $497,178.45. Following the completion of the acquisition, the chief executive officer directly owned 20,742,935 shares in the company, valued at approximately $308,447,443.45. The trade was a 0.16% increase in their position. The transaction was disclosed in a filing with the SEC, which is accessible through the SEC website.

Institutional Trading of Telix Pharmaceuticals

Hedge funds have recently added to or reduced their stakes in the company. Lazard Asset Management LLC boosted its stake in Telix Pharmaceuticals by 15.7% in the 1st quarter. Lazard Asset Management LLC now owns 289,917 shares of the company’s stock valued at $2,775,000 after purchasing an additional 39,400 shares during the period. Portland Investment Counsel Inc. increased its position in Telix Pharmaceuticals by 108.0% during the 4th quarter. Portland Investment Counsel Inc. now owns 266,200 shares of the company’s stock worth $2,063,000 after buying an additional 138,200 shares during the period. Millennium Management LLC acquired a new stake in shares of Telix Pharmaceuticals during the third quarter worth $1,883,000. Private Advisor Group LLC lifted its holdings in shares of Telix Pharmaceuticals by 276.3% during the first quarter. Private Advisor Group LLC now owns 174,415 shares of the company’s stock worth $1,669,000 after buying an additional 128,070 shares in the last quarter. Finally, Hennion & Walsh Asset Management Inc. bought a new stake in shares of Telix Pharmaceuticals in the second quarter valued at about $1,731,000.

About Telix Pharmaceuticals

Telix Pharmaceuticals (NASDAQ: TLX) is a clinical-stage biopharmaceutical company focused on the development and commercialization of molecularly targeted radiopharmaceuticals for the diagnosis and treatment of cancer. Leveraging expertise in radiochemistry, nuclear medicine and oncology, Telix aims to address unmet clinical needs across a range of tumor types by pairing diagnostic imaging agents with therapeutic radionuclides.

The company’s pipeline spans both imaging and therapeutic candidates.